EPG Online Twitter
EPG Online Blog
Disease Knowledge
Drug Updates
Treatment of disabling motor fluctuations in patients with Parkinson's disease which persist after treatment with levodopa and/or other dopamine agonists.
- Fostair 100/6 inhalation solution
- Epanutin capsules 25, 50 and 100mg
- Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe
- FemSeven Conti
- Epanutin 300mg hard capsules
- Bedranol 80mg SR Capsules
- Bedranol 160mg SR Capsules
- Betim 10mg Tablets
- Carbo-Dome Cream
- Bisoprolol 2.5mg/5mg/10mg film coated tablet
- Phenergan Injection
- Rivotril 0.5 mg and 2 mgTablets
- Rivotril Ampoules
- RELPAX 20mg and 40mg Film-Coated Tablets
- Witch Doctor ® 81.5%w/w Gel
- Levetiracetam Actavis 1,000 mg film-coated tablets
- Levetiracetam Actavis 250 mg film-coated tablets
- Levetiracetam Actavis 500 mg film-coated tablets
- Levetiracetam Actavis 750 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules
- Lidocaine Hydrochloride Injection BP 2.0% w/v
- Omeprazole 10mg Capsules
- Omeprazole 20mg Capsules
- Panadol Extra Advance 500 mg/65 mg Tablets
- Allopurinol Tablets BP 300mg
- Allopurinol Tablets BP 100mg
- Anadin Ultra Double Strength 400mg Capsules/Anadin LiquiFast 400mg Capsules
- Calcipotriol Scalp Solution
- Bupivacaine Hydrochloride Injection BP 0.5% w/v.
- Lescol (fluvastatin* sodium) 20 mg and 40 mg capsules
- Meropenem 1 g Powder for Solution for Injection or Infusion
- VALTREX Tablets 250mg
- Vesicare 5mg & 10mg film-coated tablets
- Zomig 5mg Nasal Spray
- Water for Injections
- Tizanidine 2mg Tablets
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Orfadin 10 mg hard capsules
- Orfadin 2 mg hard capsules
- Natecal D3 Chewable Tablets
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Dopamine agonists (dopaminergics) .
Apomorphine
Solution for injection in 2mL or 5mL ampoules.
Solution for injection, apomorphine hydrochloride 1.0% w/ v (10mg/mL).
Treatment of disabling motor fluctuations in patients with Parkinson's disease which persist after treatment with levodopa and/or other dopamine agonists.
For subcutaneous use by intermittent bolus injection. May also be administered as a continuous subcutaneous infusion by minipump. It is essential that the patient is established on domperidone, usually 20mg three times daily for at least two days prior to initiation of therapy.
Under 18 years, contraindicated.
Respiratory depression, dementia, hepatic insufficiency. hepatic insufficiency. Intermittent apomorphine treatment is not suitable for patients who have an 'on' response to levodopa which is marred by severe dyskinesia or dystonia. Known sensitivity to apomorphine or to any other ingredients of the product. Not recommended for use in women of child-bearing potential. Breastfeeding not recommended.
Renal, pulmonary or cardiovascular disease. Persons prone to nausea and vomiting. Elderly and/or debilitated patients. Pre-existing cardiac disease, patients taking vasoactive drugs such as antihypertensives, pre-existing postural hypotension.
Neuropsychiatric disturbance may be exacerbated by APO-go in some patients; there is also evidence from clinical studies that APO-go may improve these symtoms.
Neuroleptics, antihypertensives, cardiac active drugs.
Nausea and vomiting. Postural hypotension. Local subcutaneous injection site reactions including local induration and nodules (usually asymptomatic). Dyskinesia, neuropsychiatric disturbances. Transient sedation. Rarely, Coomb's positive haemolytic anaemia in patients treated with apomorphine and levodopa. Eosinophilia.
Britannia
(POM)
30 June 2009





